ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it will present at the Wilsons Healthcare IT Conference in Sydney on Wednesday, 30th November 2016 at 9:45am AEDT.
The goal of the conference is to demonstrate how technology can improve the efficiency of healthcare spending and enhance outcomes for patients. The invitation-only event will be attended by approximately 40 institutional investors who are new to healthcare IT and e-health investment opportunities and looking to gain a more in-depth understanding of the sector.
ResApp also advises that the startup of its US clinical study, SMARTCOUGH-C, is progressing well with recruitment to begin this quarter. Details of the study are now available on the US National Institutes of Health clinical trials database at www.clinicaltrials.gov (NCT02973282). Institutional review board approvals are in place, and Site Initiation Visits at the main sites and their multiple satellite sites will take place shortly, during which clinical staff will be trained on the final approved protocol. The Company expects rapid recruitment given the size of the participating hospitals and the onset of winter in the US when there is a high prevalence of respiratory disease.
– ENDS –
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use sound alone to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has both adult and paediatric clinical studies underway with preliminary results demonstrating accurate diagnosis of pneumonia, asthma/viral wheeze, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma and pneumonia in adults. Markets for ResApp’s technology include telehealth use through partnerships with telehealth service providers, emergency department and regular clinic use by healthcare providers, at-home use by consumers and working with global aid and humanitarian organisations to deliver tools for the developing world.
For more information on ResApp, visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.